CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CDK4/6 and PI3K inhibitors: A new promise for patients with HER2‐positive breast cancer

Published:2021-03-16 Issue:7 Volume:51 Page:
ISSN:0014-2972
Container-title:European Journal of Clinical Investigation
language:en
Short-container-title:Eur. J. Clin. Invest.

Author:

Agostinetto Elisa¹²^ORCID,Debien Véronique¹,Marta Guilherme Nader¹,Lambertini Matteo³⁴^ORCID,Piccart‐Gebhart Martine⁵,de Azambuja Evandro¹

Affiliation:

1. Academic Trials Promoting Team Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B) Brussels Belgium

2. Humanitas Clinical and Research Center – IRCCS Humanitas Cancer Center Milan Italy

3. Department of Internal Medicine and Medical Specialties (DiMI) School of Medicine University of Genova Genova Italy

4. Department of Medical Oncology U.O.C Clinica di Oncologia Medica IRCCS Ospedale Policlinico San Martino Genova Italy

5. Oncology Department Institut Jules Bordet Brussels Belgium

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/eci.13535

Reference88 articles.

1. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review

4. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PTEN neddylation aggravates CDK4/6 inhibitor resistance in breast cancer;2024-08-07

2. Combined targeted therapy with PI3K and CDK4/6, or FGFR inhibitors show synergistic effects in a neuroblastoma spheroid culture model;Biomedicine & Pharmacotherapy;2024-08

3. The role of targeting CDK4/6 in cancer immunotherapy;Holistic Integrative Oncology;2024-06-27

4. Impact of HER2‐low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR‐positive/HER2‐negative metastatic breast cancer: A prospective study;Thoracic Cancer;2024-03-13

5. Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance;International Journal of Clinical and Experimental Pathology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3